XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp.: XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

XPhyto Therapeutics Corp.: XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips

XPhyto Therapeutics Corp.: XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

XPhyto Therapeutics Corp.: XPhyto announces European Approval for 25 Minute COVID-19 PCR Test

XPhyto Therapeutics Corp.: XPhyto Completes Corporate Rebranding and Launches New Website

XPhyto Therapeutics Corp.: XPhyto Places First Order for 25-Minute Covid-19 RT-PCR Tests

XPhyto Therapeutics Corp.: XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs

XPhyto Therapeutics Corp.: XPhyto Announces Psychedelic Pharmaceutical Production Agreement

XPhyto Therapeutics Corp.: Parkinson’s Generic Transdermal Drug Delivery System